Association of beta-Amyloid Level, Clinical Progression, and Longitudinal Cognitive Change in Normal Older Individuals
Laura M Van der Kall, Truong Thanh, Samantha C Burnham, Vincent Dore, Rachel S Mulligan, Svetlana Bozinovski, Fiona Lamb, Pierrick Bourgeat, Jurgen Fripp, Stephanie Schultz, Yen Y Lim, Simon M Laws, David Ames, Christopher Fowler, Stephanie R Rainey-Smith, Ralph N Martins, Olivier Salvado, Joanne Robertson, Paul Maruff, Colin L Masters Show all
NEUROLOGY | LIPPINCOTT WILLIAMS & WILKINS | Published : 2021
OBJECTIVE: To determine the effect of β-amyloid (Aβ) level on progression risk to mild cognitive impairment (MCI) or dementia and longitudinal cognitive change in cognitively normal (CN) older individuals. METHODS: All CN from the Australian Imaging Biomarkers and Lifestyle study with Aβ PET and ≥3 years follow-up were included (n = 534; age 72 ± 6 years; 27% Aβ positive; follow-up 5.3 ± 1.7 years). Aβ level was divided using the standardized 0-100 Centiloid scale: 100 CL very high, noting >25 CL approximates a positive scan. Cox proportional hazards analysis and linear mixed effect models were used to assess risk of progression and cognitive decline. RESULTS: Aβ levels in 63% were negative,..View full abstract
Core funding for the study was provided by the CSIRO Flagship Collaboration Fund and the Science and Industry Endowment Fund in partnership with Austin Health, University of Melbourne, Edith Cowan University, Florey Institute of Neuroscience and Mental Health, Alzheimer's Australia, and the National Ageing Research Institute. The study also received funding from the National Health and Medical Research Council, the Dementia Collaborative Research Centres program, the McCusker Alzheimer's Research Foundation, and Operational Infrastructure Support from the Government of Victoria.